Articles

  • 2 months ago | parkinsonsnewstoday.com | Andrea Lobo |Diana Delgado |Lindsey Shapiro |Margarida Maia

    Newronika is preparing for the commercial launch of AlphaDBS — a next-generation adaptive deep brain stimulation (DBS) system for treating Parkinson’s disease — at selected markets in Europe this year, following CE Mark approval in the European Union.

  • Feb 28, 2025 | parkinsonsnewstoday.com | Marisa Wexler |Mollie Lombardi |Lindsey Shapiro |Diana Delgado

    Treatment with psilocybin — the hallucinogenic agent in magic mushrooms — may help to prevent damage to the brain following mild head injuries, according to a new study done in rats. Head injuries are an established risk factor for Parkinson’s disease, as well as Alzheimer’s and other forms of dementia. The study, “Psilocybin as a Treatment for Repetitive Mild Head Injury: Evidence from Neuroradiology and Molecular Biology,” was published online as a preprint.

  • Jan 13, 2025 | cysticfibrosisnewstoday.com | Andrea Lobo |Margarida Maia |Marisa Wexler |Diana Delgado

    A Phase 1b trial assessing the safety of RCT2100, Recode Therapeutics’ inhaled therapy candidate for people with cystic fibrosis (CF), has now dosed its first patient in the U.S. The trial already was underway in Europe. RCT2100 is being developed for patients who do not respond to or are not eligible for CFTR modulator therapies — individuals who, according to the company, account for about 10% of the CF community.

  • Mar 25, 2024 | ancavasculitisnews.com | Margarida Maia |Diana Delgado |Steve Bryson |Marta Costa Figueiredo

    ANCA-associated vasculitis (AAV) patients receiving a cumulative dose of at least 935 mg of glucocorticoids over six months are more likely to see clinically meaningful side effects, according to a study using calculations based on the Glucocorticoid Toxicity Index (GTI). The findings suggest the GTI, which considers the frequency and severity of glucocorticoid-related side effects, may help identify who’s at a higher risk for side effects in research and clinical settings.

  • Feb 19, 2024 | parkinsonsnewstoday.com | Mary M. Chapman |Marisa Wexler |Mary Beth Skylis |Diana Delgado

    Parkinson’s disease patients who experience tremor are invited to complete an online survey aimed at assessing the difficulties due to this common disease symptom, with an ultimate goal of promoting more effective treatments.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →